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Linkage disequilibrium (LD) mapping offers much promise for the positional cloning of disease-causing genes.
However, conventional estimates of LD may fluctuate substantially across contiguous genomic regions, because of
population-specific phenomena such as mutation, genetic drift, population structure, and variations in allele fre-
quencies. This fluctuation makes it difficult to interpret patterns of LD and distinguish where a causal gene is
located. To address this issue, we propose hierarchical modeling of LD (HLD) for fine-scale mapping. This approach
incorporates information on haplotype block structure and chromosomal spatial relations to refine the pattern of
LD, increasing the ability to localize disease genes. Here, we present a framework for HLD, a simulation study
assessing the performance of HLD under various scenarios, and an application of HLD to existing data. This work
demonstrates that hierarchical modeling of linkage disequilibrium is a valuable and flexible approach for fine-scale
mapping.
Introduction
Recent technological advances have made feasible rapid
identification and sequencing of large numbers of genetic
markers (e.g., SNPs) (Collins et al. 1998; Risch 2000).
Many closely spaced markers allow for a trait locus to
be localized by measurement of the allelic association
due to linkage (i.e., linkage disequilibrium [LD]) be-
tween the markers and a putative disease-predisposing
locus (Devlin and Risch 1995). This fine-mapping ap-
proach focuses on refining the resolution of the location
of a disease-susceptibility gene through estimation and
interpretation of the pattern of LD, rather than on test-
ing the statistical significance of LD. Thus, this assumes
a priori support—from either linkage studies or biolog-
ical information—for the potential existence of a disease-
susceptibility gene within a region of interest.
Ignoring population-specific history and structure,
the pairwise measure of LD is primarily a function of
time and distance between markers and a disease-pre-
disposing locus. If the number of generations since the
introduction of a disease-causing allele is sufficiently
large to allow for several meiotic events between the
markers and if the alleles have not yet returned to equi-
librium, we would expect a pattern of LD over all mark-
ers in a specific region to have a single peak, occurring
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at or near the disease-causing locus (Devlin and Risch
1995). Although such patterns of LD have been ob-
served in real populations and have been predicted in
theoretical models, their interpretation is not always
straightforward (Abecasis et al. 2001; Pritchard and
Przeworski 2001). In particular, allelic associations may
not reflect tight linkage along a chromosomal segment
but instead may be due to population phenomena, such
as genetic drift, mutation, nonrandom mating, and se-
lection (Nordborg and Tavare 2002). These phenomena
can also lead to fluctuations in the measures of LD.
Moreover, all measures of LD depend to various degrees
on the allele frequency at each marker (Hedrick 1987;
Lewontin 1988).
These potential disruptions in the pattern of pairwise
measures of LD can make narrowing the location of a
disease-predisposing polymorphism extremely difficult.
In many instances, the haplotype structure may better
explain the underlying disease-marker relations and
provide more power for detecting disease associations
(Bader 2001; Kaplan and Morris 2001; Morris and
Kaplan 2002). However, haplotype analyses may suffer
because of phase uncertainty and complexities in eval-
uating the numerous haplotypes that are possible when
several markers are available (Clayton and Jones 1999).
Furthermore, in light of recent work showing the hap-
lotype block structure of the human genome (Daly et
al. 2001; Goldstein 2001; Jeffreys et al. 2001; Johnson
et al. 2001; Reich et al. 2001; Gabriel et al. 2002; Patil
et al. 2001), most causal variant(s) will reside on as-
sociated haplotypes. This makes it extremely difficult to
localize a narrow “causative” region within the hap-
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lotype or to distinguish the causal variant(s) from the
haplotype association.
We can address the extreme fluctuations in pairwise
measures of LD by incorporating information regarding
higher-order genetic structure and the spatial relations
among the markers into a hierarchical model. Specifi-
cally, this approach uses information in a second-stage
model such as haplotype structure and/or intermarker
distance along a chromosome in an attempt to obtain
better estimates of LD. Hence, the hierarchical linkage
disequilibrium (HLD) estimates will reflect both how
well the pairwise measures of LD are estimated and the
particular underlying genetic structure of the chromo-
somal region.
Previous work has shown that hierarchical modeling
can considerably improve conventional estimation
(Morris 1983; Greenland 1993). This approach has
been proposed to improve association studies (Witte
1997), to control for spurious associations due to pop-
ulation stratification (Kim et al. 2001; Sillanpaa et al.
2001), to group haplotype effects (Thomas et al. 2001),
and to make correlation inference in behavioral genetic
analysis (Guo and Wang 2002). In addition, Clayton
(2000) discusses methods of LD mapping that use iden-
tity-by-descent, haplotype sharing, and various popu-
lation genetic models within a hierarchical framework
to account for the covariance between markers. In this
article, we further develop hierarchical modeling to re-
fine patterns of LD by incorporation of underlying hap-
lotype structure and spatial relations among closely
spaced markers. After presenting themodel, we evaluate
its performance through a simulation study and apply
it to existing data.
Methods
First-Stage Model
Assume we undertake an association study for fine-
scale LD mapping of a binary trait Y (e.g., if diseased,
) with M finely spaced markers, . OneYp 1 x ,… ,x1 M
measure of LD is the log of the odds ratio, , which canbm
be estimated from logistic regression
T Tlogit[Pr (Yp 1)x ]p m  x b , (1)m m m m
where is a vector of marker-specific coding for theTxm
individuals under study. In particular, given a particular
marker, m, with two-alleles, A and a, we have the fol-
lowing genotypic coding options for f(genotype):
, , , where , 0.5, 1 forf(aa)p 0 f(Aa)p d f(AA)p 1 dp 0
recessive, additive, or dominant models, respectively. If
the above coding yields a negative estimate of , webm
can use the reciprocal coding to obtain a positive esti-
mate—that is, , , . Assum-f(aa)p 1 f(Aa)p d f(AA)p 0
ing Hardy-Weinberg equilibrium and treating the alleles
rather than people as observations, an additional coding
option models the effects of one additional allele on
disease using f(allele): , ; or ,f(A)p 1 f(a)p 0 f(a)p 1
(Sasieni 1997). The positive estimates off(A)p 0 bm
from equation (1) can be used to assess the spatial pat-
terns of LD and refine the location of a potential disease-
predisposing polymorphism.
Although there are many other measures of LD (Dev-
lin and Risch 1995; Collins et al. 2001), we use the log
of the odds ratio here because it provides a symmetric
measure of LD between two loci and is invariant to
changes in marginal frequencies due to oversampling of
disease chromosomes (Edwards 1963). Moreover, logis-
tic regression (1) allows one to include covariates in the
model. Nevertheless, as with all measures of LD, the
patterns arising when using the log of the odds ratio for
fine mapping may substantially fluctuate because of pop-
ulation history, structure, and allele frequency differ-
ences between the markers (Lewontin 1988; Clayton
2000). In addition, if the association study has a small
sample size, the first-stage estimates of LDmay be highly
unstable and biased (Greenland et al. 2000).
Second-Stage Model
We can attempt to improve the first-stage log odds
ratio estimates—and thus to refine the pattern of LD—by
specifying a second-stage model. In particular, we can
model the log of the odds ratios, , as aTbp (b ,… ,b )1 M
simple linear function of marker specific covariates and
a random effect,
bp ZpU , (2)
2( )U ∼ N 0 ,t T . (3)m m
Z is a second-stage designmatrix containing information
about the relations among markers, is a column vectorp
of coefficients corresponding to the effects on disease of
the marker-specific relations defined in Z, are randomU
effects reflecting the residual log odds ratio after ad-
justment for marker level risk factors and/ormarker level
relations defined in Z, 0m is an m # 1 vector of zeros,
and t2T is an m # m covariance matrix.
Z incorporates into a second stage the chromosomal
structure of the genetic markers, whereby the estimate
of each bm “borrows” information from the other esti-
mates. For example, recent work shows the potential for
markers to cluster into regions of high inter-marker link-
age disequilibrium or haplotype blocks, separated by
localized hot spots of recombination (Daly et al. 2001;
Goldstein 2001; Jeffreys et al. 2001; Johnson et al. 2001;
Conti et al.: Hierarchical Linkage Disequilibrium 353
Reich et al. 2001; Gabriel et al. 2002; Patil et al. 2001).
For such genetic structure, the Z matrix could be com-
posed of indicator variables distinguishing which mark-
ers are in a particular haplotype block or cluster. Those
within the same block would thus borrow information
from one another to improve estimation. Moreover, the
estimated reflect the effect of each haplotype block onp˜
disease.
The residual variability for the measures of LD may
be incorporated in a second-stage model through the
specification of the covariance matrix, t2T, for the ran-
dom effects, . This is essentially a smoothing param-U
eter, where t2 controls the overall level of smoothing,
and the structure of T defines the intricacies of the
smoothing. If there is only unstructured variability along
the chromosome, T can equal the identity matrix. If we
believe that the residual effects have a spatial depen-
dence, as is likely for measures of LD along particular
chromosomal segments, we can model the log of the
odds ratios with a spatially structured model (Richard-
son et al. 1992; Pascutto et al. 2000). Here, we can
specify T with a distance function, , wheret p g(d ,V)ml ml
dml is the distance between marker m and marker l, and
V represents additional parameters that are needed to
define the spatial dependence between m and l. For fine-
scale mapping, we can use a general exponential decay
function of spatial dependence relative to inter-marker
distance (Wakefield et al. 2000),
g(d ,Vp {v ,v })ml 1 2
v2dmlp exp  ,v ,v  (0,2] , (4)1 2( )[ ]v1
where v1 and v2 determine the degree of spatial depen-
dence and the distance, dml, can reflect marker adjacency,
or physical or genetic distance between markers. Here,
we prespecified v1 and v2. For positive spatial depen-
dence, v2 is restricted, because results in a covar-v 1 22
iance matrix with both theoretical and practical diffi-
culties (Diggle et al. 1998). One may also choose to
estimate the spatial dependence from the data (Wakefield
et al. 2000).
The final structure of T is a function of the distance
metric used for dml and our prior belief in the spatial
dependence between the markers. By defining distance
as a function of adjacency, we assume that the distance
between each marker is uniform across the chromosomal
region. If more information is available regarding map
locations, then more accurate spatial relations may be
specified using physical or genetic distance for dml. Al-
though either distance provides additional resolution,
the most appropriate choice is that which best reflects
the spatial dependence between the markers. For certain
sets of markers, genetic distance may best reflect the
spatial dependence due to recombination. Nevertheless,
previous work on hierarchical modeling shows that sub-
tle differences in specification of the second-stage model
do not necessarily have a large impact on the improve-
ment available with this approach (Witte andGreenland,
1996). To fit the hierarchical model, one can use a two-
stage estimation procedure (see appendix A).
Simulation Study
To evaluate the potential gains of a spatially structured
HLD model over conventional pairwise LD, we under-
take a fundamental simulation study. Specifically, we use
a forward-in-time procedure to simulate a chromosomal
region with a single causal variant and an expected un-
imodal pattern of LD. We ignore mutation to evaluate
the resulting variation in the measures of LD due only
to recombination, allele frequency differences across the
markers on the chromosome, differences in attributable
fractions for the causal variant, and limited stochastic
evolution (i.e., variation resulting from population his-
tory). Although a coalescent model may allow for sim-
ulations that are more representative of certain human
populations, we simulate under optimal conditions for
conventional pairwise LD (i.e., expected unimodal pat-
tern and restricted causes of variation) to gauge any
potential improvement using HLD.
For each of 1,000 trials, we simulate a population of
20,000 individuals with a disease prevalence of 5% and
allow them to mate randomly for 50 generations. We
then sample 500 case individuals and 500 control in-
dividuals from the resulting population. Fourteen SNPs
are initially in complete disequilibrium (i.e., for′D p 1
all markers) with a simulated disease polymorphism,
located halfway between the seventh and eighth SNPs.
Recombination is simulated as a Poisson process with
the rate determined by the SNP spacing along the chro-
mosome. We simulate scenarios with a range of loca-
tions and allele frequencies for the SNPs, various disease
allele frequencies, multiple attributable fractions, and
genetic relative risks for the disease polymorphism (de-
scribed in table 1). The specific genetic model for each
scenario is defined by the following equations for the
disease prevalence
2 2Kp p f  2p p f  p f , (5)1 11 1 0 10 0 00
the attributable fraction
f f2 11 10p  1 2p p  1( ) ( )1 1 0f f00 00
AFp , (6)
f f2 11 10p  1 2p p  1 1( ) ( )1 1 0f f00 00
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Table 1
Results from Simulation Study Comparing Conventional Linkage Disequilibrium with Hierarchical Linkage Disequilibrium (HLD)
SCENARIO
MARKER
ALLELE
FREQUENCIES
MARKER
SPACING (cM) ap1 AF
b GRRc GRRd
RATIO OF HLD TO FIRST-STAGE LDg
FIRST-STAGE
LD tp .05 tp .1 tp .15
Neare MSEf Near MSE Near MSE Near MSE
1 Constant (.5) Constant (.5) .3 .6 3.5 6.0 91.1 .11 1.06 .36 1.04 .51 1.03 .68
2 Constant (.5) Constant (.5) .3 .3 1.7 2.4 60.5 2.00 1.14 .69 1.12 .77 1.08 .85
3 Constant (.5) Constant (.5) .3 .1 1.2 1.4 28.0 9.30 1.01 1.00 1.01 .98 1.01 .98
4 Constant (.1) Constant (.5) .3 .6 3.5 6.0 71.8 .89 1.20 .32 1.19 .35 1.18 .39
5 Constant (.1) Constant (.5) .3 .3 1.7 2.4 45.9 4.36 1.29 .66 1.30 .66 1.24 .71
6 Constant (.1) Constant (.5) .3 .1 1.2 1.4 23.4 9.62 1.08 1.02 1.09 1.04 1.06 1.05
7 Constant (.5) Random (.3–.8) .3 .6 3.5 6.0 91.9 .10 1.05 .35 1.05 .37 1.03 .59
8 Constant (.5) Random (.3–.8) .3 .3 1.7 2.4 62.4 2.05 1.15 .52 1.12 .60 1.08 .73
9 Constant (.5) Random (.3–.8) .3 .1 1.2 1.4 28.3 8.52 1.06 1.05 1.08 1.03 1.05 1.03
10 Random (.1–.9) Constant (.5) .3 .6 3.5 6.0 71.0 .64 1.03 .66 1.02 .70 1.03 .72
11 Random (.1–.9) Constant (.5) .3 .3 1.7 2.4 56.0 2.46 1.03 .77 1.07 .71 1.09 .77
12 Random (.1–.9) Constant (.5) .3 .1 1.2 1.4 23.8 9.89 1.18 .96 1.16 .96 1.14 .96
13 Random (.1–.9) Random (.3–.8) .3 .6 3.5 6.0 72.3 .64 1.02 .82 1.02 .78 1.03 .82
14 Random (.1–.9) Random (.3–.8) .3 .3 1.7 2.4 56.2 2.65 1.06 .77 1.08 .79 1.06 .82
15 Random (.1–.9) Random (.3–.8) .3 .1 1.2 1.4 27.2 9.13 .98 1.02 1.03 1.01 1.00 1.00
16 Constant (.5) Constant (.5) .1 .6 8.5 16.0 88.2 .19 1.09 .19 1.09 .26 1.06 .40
17 Constant (.5) Constant (.5) .1 .3 3.1 5.3 62.1 1.84 1.18 .48 1.13 .63 1.10 .74
18 Constant (.5) Constant (.5) .1 .1 1.6 2.1 28.9 8.54 1.08 .98 1.06 .97 1.07 1.01
19 Constant (.5) Constant (.5) .5 .6 2.5 4.0 98.7 .01 1.00 .69 1.01 .54 1.01 .46
20 Constant (.5) Constant (.5) .5 .3 1.4 1.9 77.2 1.50 1.02 .90 1.03 .87 1.02 .94
21 Constant (.5) Constant (.5) .5 .1 1.1 1.2 31.3 9.44 1.04 .98 1.07 .99 1.03 .98
a The disease allele frequency.
b Population attributable fraction.
c GRR Heterozygote .p f /f10 00
d GRR Homozygote .p f /f11 00
e Percent of simulations with the largest estimate of LD nearest to the disease gene.
f Mean squared error for the distance from the disease locus to the marker with the largest estimate of LD.
g Ratio of corresponding measure of performance from HLD to first-stage LD. For Near, values 11.0 indicate HLD improvement. ForMSE,
values !1.0 demonstrate a refinement in the LD pattern.
and the relation of the penetrances (Kaplan and Morris
2001)
f  f10 00
jp .
f  f11 00
For all the scenarios, we assume that andf 1 f 1 f11 10 00
(i.e., an additive model).jp 0.5
To analyze the resulting case-control data, we use a
first-stage logistic regression with a log-additive coding
( ) for the genotypes at each SNP. The second-dp 0.5
stage model is spatially structured, with the dependence
determined by an exponential decay function (eq. [4],
, ) to define the second-stage corre-v p 1,000 v p 11 2
lation matrix, T, and a 14 # 1 vector of ones for the
second-stage design matrix, Z. This should smooth the
first-stage estimates towards a global mean—the extent
of smoothing for each marker defined by the inverse-
variance weight (A2) and the estimates of the surround-
ing markers. We fit the model with three prespecified
values for t (0.5, 0.1, 0.15), to test the sensitivity of the
posterior estimates.
The performance of these models is assessed with the
following two measures (Devlin and Risch 1995): (1)
the number of times in 1,000 trials that the marker with
the largest measure of LD is next to the disease-causing
polymorphism (Near); and (2) the mean squared error
using the distance from the disease locus to the marker
with the highest measure of LD, given in number of
markers (MSE). The first reflects localization of the dis-
ease-causing SNP, and the second refinement of the LD
pattern.
The results from the simulation study are presented
in table 1. For comparison, we give the observed values
for the conventional first-stage LD, and the ratio of the
HLD results to these values (i.e., calculated by dividing
the performance measure for HLD by the corresponding
measure obtained from the conventional first-stage
analysis). Hence, a ratio of 1.0 indicates that the con-
ventional and HLD approaches give identical results;
departures from 1.0 show the improvement of one ap-
proach over the other. In particular, ratios above 1.0
for Near and below 1.0 for MSE indicate improvement
of HLD over the conventional one-stage analysis.
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Table 2
Results from Simulation Study Comparing Conventional
Linkage Disequilibrium with Hierarchical Linkage
Disequilibrium (HLD)
AVERAGE
VALUE
FOR
RATIO OF HLD TO FIRST-STAGE LD
tp .05 tp .1 tp .15
Near MSE Near MSE Near MSE
AFp 0.6 1.06 .48 1.06 .50 1.05 .58
AFp 0.3 1.12 .68 1.12 .72 1.09 .79
AFp 0.1 1.06 1.00 1.07 1.00 1.05 1.00
Overall 1.08 .72 1.08 .74 1.07 .79
In 111 of 126 measurements, HLD did better than
LD, with four measures indicating equivalent perform-
ance. Across all scenarios, the total average ratio for
Near shows that there is an 8% increase in the per-
formance of HLD over LD in localizing the disease-
causing gene (table 2). Additionally, HLD substantially
reducesMSE (a 25% reduction, on average), indicating
a considerable refinement in the LD pattern. The trend
of the average ratio across each attributable fraction
(AF) shows a maximum improvement for locating the
disease locus when the AF is modest, (an 11%AFp 0.3
increase, on average, for Near). This improvement is
smaller for more extreme values (i.e., andAFp 0.1
), with an average of a 6% increase in per-AFp 0.6
formance. For pattern refinement, as indicated byMSE,
the maximum improvement from using HLD occurs for
high AF (a 48% reduction on average for MSE). This
improvement decreases as the AF decreases. Further-
more, the average ratio within each AF shows that HLD
improves upon conventional LD across all the three
prespecified values for t, with a slight trend of increased
relative performance as t decreases.
For the simple situations when the marker allele fre-
quencies are moderate and constant, the marker spacing
is constant, and the disease allele frequency is modest
(scenarios 1–3), HLD demonstrates both an improve-
ment in the localization (Near) and in pattern refine-
ment (MSE). When scenarios 1–3 are used as a standard
for comparison, and when the marker allele frequencies
are rare but remain constant (scenarios 4–6), the first-
stage LD estimates perform poorly. For these scenarios,
there is an increase in the relative improvement of HLD
to detect the disease locus. Randomization of the
marker spacing (scenarios 7–9) has little effect on the
performance of the first-stage estimates and the relative
increase in performance using HLD. Fluctuations in the
pattern of the log odds ratio are greatest when the
marker allele frequencies vary along the chromosomal
region. This is reflected in the decreased performance
of the first-stage LD estimates when the allele frequen-
cies are randomized (scenarios 10–15). While the ability
of HLD to improve upon the first-stage estimates is
maintained for these situations, its relative improvement
over conventional LD is diminished. Finally, when the
disease allele frequency is rare (scenarios 16–18), HLD
shows greater improvement for localization and pattern
refinement. Increasing the disease allele frequency (sce-
narios 19–21) results in better performance of the first-
stage estimates. As conventional LD performance in-
creases, it is more difficult for HLD to demonstrate
dramatic improvements. Nevertheless, HLD is still able
to enhance conventional estimation and clarify the LD
pattern.
Application of HLD
We illustrate HLD with data previously used to examine
the pattern of LD and the underlying haplotype structure
for a 500-kb region on chromosome 5q31 (Daly et al.
2001). The data consist of 103 “common” SNPs (i.e.,
with minor allele frequencies 15%). Daly et al. (2001)
used a hidden Markov model to determine 11 haplotype
blocks (groups of loci with low diversity), presumably
separated by local hotspots of recombination. They then
used this underlying block information to refine the pat-
tern of LD. We extend this work by using the haplotype
blocks in a hierarchical model. This results in the indi-
vidual pairwise estimates of LD “borrowing” informa-
tion from all the markers within the same block.
To approximate a conventional population-based
case-control study, we select the offspring in each of
129 family trios for analysis. Similar to Daly et al.
(2001; see their fig. 1c and 1d), we used SNP 61, located
at 579 kb, as the disease-causing locus. For our analyses,
the frequency of the disease allele at SNP 61 is 30%,
resulting in 30% of the sample being defined as cases,
and the remaining 70% as controls. Individuals with
missing data for SNP 61 were excluded from our ap-
plication, leaving 105 individuals and 97 noncausal
SNPs for the analysis.
Our aim is to examine how the pattern of LD for the
97 noncausal SNPs is refined under different specifi-
cations of the hierarchical model and varying levels of
information. For all analyses, we choose to examine the
log of the odds ratio associated with a single allele in-
crease as our measure of LD and we investigate three
second-stage models (denoted here as “A,” “B,” and
“C”). Model A is a spatially structured model with the
relations in the residual matrix, T, determined by an
exponential decay function (5), where ,v p 7,0001
, and equals the distance, in bases, betweenv p 1 d2 ml
two markers. The second-stage design matrix, Z, is a
97# 1 vector of ones. In general, this model will shrink
the first-stage estimates toward a global mean for all
the markers, using the spatial relations of the surround-
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Figure 1 Second-stage design matrix using the haplotype blocks
and SNP labels from Daly et al. (2001).
ing markers to determine the degree of shrinkage for
each marker.
Model B is an unstructured hierarchical model with
T equal to the identity matrix and the second-stage de-
sign matrix, Z, determined by the underlying haplotype
block structure defined by Daly et al. (2001) (fig. 1).
We assigned four SNPs not classified by Daly et al.
(2001) to the block immediately upstream. In model B,
the HLD estimates are a weighted average of the first-
stage pairwise estimates and the second-stage means for
each haplotype block, . By using an unstructured˜Zp
residual variance, we assume that it is uniform across
all markers within the chromosomal region. Model C
is a spatially structured model combining the properties
of models A and B to incorporate both spatial depen-
dence and block information. The HLD estimates will
be weighted toward the second-stage means for each
haplotype block with the extent of shrinkage deter-
mined by the spatial dependence of each marker along
the chromosomal region. To examine the sensitivity of
the HLD estimates to t, all models were performed using
three different values for t (0.2, 0.35, and 0.5).
Figure 2 presents patterns of LD for the first-stage,
second-stage, and hierarchical model estimates. The
first-stage log odds ratios yield a peak, at the location
of the disease-predisposing locus, more distinct than the
measure of D′ used by Daly et al. (2001). Note, however,
that the resulting pattern of LD from our analysis using
the log of the odds ratio is not directly comparable to
the analysis in Daly et al. (2001), which aims to examine
the underlying haplotype relations using D′, a measure
sensitive mostly to recombination. Although the two
highest first-stage estimates of LD are located adjacent
to the disease locus at SNP 62 and SNP 63, greater
dependence of the log odds ratio on allele frequency
results in increased variability in the estimates across
the chromosomal region, compared with D′. For ex-
ample, in the region from 520 to 620 kb, the range of
the first-stage estimates of the log odds ratio is large,
from 0.54 (SNP 75) to 6.13 (SNP 62). In contrast, for
model A with in figure 2, the range of esti-tp 0.35
mates is much smaller, from 1.82 (SNP 75) to 4.41 (SNP
60). Reducing the variability for all of the estimates
refines the overall pattern of LD and clarifies the region
with the disease predisposing locus. By defining Z with
marker inclusion into haplotype blocks, each estimated
second-stage effect, , is equal to the mean for all mark-p˜
ers within the same block. The patterns of these esti-
mates provide additional support for localizing the dis-
ease. However, instead of relying solely on the haplotype
block estimates, HLD incorporates this information to
reduce the variability in the pairwise measures of LD.
As demonstrated in figure 2 , model B, we maintain the
ability to resolve the disease location that is provided
by the HLD pairwise measures, while gaining regional
support from the second-stage estimates.
The measures of LD in the 100-kb region around the
predisposing locus, which correspond to block 7 in Daly
et al. (2001) (515 kb to 615 kb), help to elucidate the
influence of spatial dependence and genetic structure.
Focusing on the models with in figure 3, thetp 0.35
spatially structured model A only slightly reduces the
variation in the estimates, but maintains the ability to
locate the disease-causing locus. For model B, the heavy
weighting of the first-stage estimates toward the second-
stage mean for block 7 greatly reduces their variability,
but the resolution of the LD peak is substantially di-
minished. In contrast, model C reduces the variation in
LD estimates and maintains the ability to resolve the
location of the disease-causing locus. Thus, as we move
from treating the markers as independent to incorpo-
rating more intermarker relations, our ability to reduce
the fluctuations in the pattern of LD and to localize the
disease gene increases.
Figure 3 demonstrates the shrinkage of the first-stage
log odds ratios toward the second-stage mean, a cor-
responding reduction of the SEs, and the sensitivity of
the results to the choice of t. Model A with tp 0.2
shows a substantial amount of weighting of the first-
stage log odds ratios towards the second-stage global
mean, 2.04. In addition, there is a considerable decrease
in the SEs associated with the final HLD estimates. In
comparison—and as expected—the model with tp
shows less weighting towards the second-stage0.5
mean; the first-stage estimates dominate the HLD es-
timates obtained from equation (A1). In parallel, there
is also less reduction in the SEs.
As noted in the methods section, the amount of
shrinkage of the first-stage log odds ratio toward the
second-stage mean is a function of the precision of the
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Figure 2 Linkage disequilibrium patterns for the Daly et al. (2001) data using spatial relations only (model A), haplotype blocks (model
B), and both spatial relations and haplotype blocks (model C). Unblackened circles () indicate the first-stage estimates of the log odds ratio.
Blackened circles (●) indicate the HLD estimates from the corresponding hierarchical model. The solid lines are the second-stage regression
coefficients, . The vertical dashed line identifies the location of the “disease” locus at SNP 61 (579 kb).p˜
first-stage estimates. This is illustrated by examining
two SNPs (45 and 46) within block 7 (table 3). Although
SNPs 45 and 46 have similar first-stage estimates, the
SE of the log odds ratio for SNP 45 is much greater,
resulting in more shrinkage toward the second-stage
mean and thus, different HLD estimates.
In addition to this case-control illustration, we use
HLD to investigate the association between the 103
SNPs in the 5q31 region and Crohn disease (Rioux et
al. 2001). Specifically, with the original 129 family trios,
we use a transmission/disequilibrium test (TDT) anal-
ysis to obtain first-stage estimates of LD (Spielman and
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Table 3
Illustrative Results Comparing Conventional Linkage
Disequilibrium (LD) to Hierarchical Linkage
Disequilibrium (HLD)
SNP
LOCATION
(kb)
LOG ODDS RATIO (SE)
First-Stage LD HLD Model Ba
45 520 2.90 (1.08) 3.46 (.35)b
46 522 3.02 (.42) 3.32 (.27)b
NOTE.—Data from Daly et al. (2001).
a Model B uses haplotype block information as a sec-
ond-stage.
b The second-stage log odds ratio for haplotype block
7 in model B is 3.52.
Figure 3 Shrinkage of conventional linkage disequilibrium estimates by hierarchical modeling. The first-stage estimates of the log odds
ratio (LD) and the SEs are paired with the corresponding posterior estimates from the hierarchical model (HLD). For the log odds ratio, the
first-stage LD estimates are shrunk toward the second stage global mean for model A, 2.04. The degree of shrinkage reflects the value of t.
Ewens 1996). We then apply hierarchical model C, us-
ing the exponential decay spatial dependence and hap-
lotype block information (fig. 1) in an attempt to refine
the pattern of LD. Rioux et al. (2001) determined 11
SNPs that are unique to the risk haplotype (table 4).
Although these SNPs contain very similar genetic in-
formation in terms of their ratio of transmitted to un-
transmitted chromosomes and their underlying haplo-
type, HLD distinguishes the effect of the individual
SNPs on Crohn disease, with the incorporation of spa-
tial dependence and block structure. Along the entire
5q31 region, HLD refines the LD pattern (fig. 4). We
observe substantial support for an association within
an ∼250–350 kb region, as seen in the work of Rioux
et al. (2001). Moreover, the HLD analysis implicates
two narrow peaks, centered approximately at 435 kb
and 620 kb, and provides additional support from the
second-stage effect estimates for each haplotype block.
Discussion
We demonstrate here how one can use HLD for fine-
scale mapping of disease genes. This approach incor-
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Table 4
LD Mapping for 5q31 and Crohn Disease
SNP NAMEa
POSITION
(kb)
HAPLOTYPE
BLOCK T:Ub ORc
HIERARCHICAL
MODEL
d˜exp (b )HLD
e
˜exp (p)
IGR2055a_1 435.0 4 87:39 2.23 2.15 1.92
IGR2060a_1 437.5 4 81:34 2.38 2.26 1.92
IGR2063b_1 439.0 4 87:37 2.35 2.21 1.92
IGR2078a_1f 446.5 48:16 3.00
IGR2096a_1 455.5 4 75:32 2.34 2.14 1.92
IGR2198a_1 506.5 5 87:41 2.12 1.62 1.57
IGR2230a_1 522.5 7 67:28 2.39 1.97 1.72
IGR2277a_1f 546.0 79:37 2.14
IGR3081a_1 609.0 7 79:35 2.26 1.75 1.72
IGR3096a_1 616.5 8 89:42 2.12 2.83 1.95
IGR3236a_1 686.5 10 79:39 2.03 2.01 1.57
a Eleven significant SNPs from Rioux et al. (2001).
b Ratio of the numbers of transmitted (T) chromosomes to untransmitted (U)
chromosomes.
c OR from a TDT analysis.
d OR from the first-stage HLD analysis.
e OR for the second-stage haplotype block effects.
f Markers not found in the Daly et al. (2001) data. Values for position, T:U, and
OR are from Rioux et al. (2001).
porates higher-level information on genetic structure and
the spatial relations of markers along a chromosomal
region to improve the localization of disease-causing
genes. HLD has two primary effects on estimates of LD.
First, the inverse variance weighting of the first- and
second-stage estimates yield final HLD estimates which
are more stable when the data are sparse. Second, “bor-
rowing” information from surrounding markers may re-
duce the impact that population history and structure
have on LD estimation. This results in more stable es-
timates of LD and increased clarity in the interpretation
of LD patterns. Our simulation study indicates that this
improvement can be substantial. For modest attributable
fractions the resolution of the disease gene location is
greatly enhanced, while improved pattern refinement oc-
curs for higher attributable fractions. The flexibility and
potential value of HLD is further shown in our appli-
cations to the data from Daly et al. (2001) and Rioux
et al. (2001), where the incorporation of both spatial
relations and genetic structure refines the pattern of LD,
provides regional support through haplotype block ef-
fect estimates, and increases the precision of the pairwise
estimates of LD.
In related work, methods have been developed for
incorporating the correlations that exist among neigh-
boring markers across chromosomal regions. Lazzeroni
(1998) and Cordell and Elston (1999) apply curve-fit-
ting procedures across the first-stage estimates by in-
tegrating marker correlations into the fitting process. If
haplotype information is available, these methods may
use a bootstrap or multinomial approximation to esti-
mate the first-stage covariance matrix, . An extensionˆV
of these approaches could use this estimated correlation
matrix in a hierarchical model, in which spatial relations
are also included. The final posterior estimates would
be a weighted average based upon the estimated sam-
pling variation and the prior spatially structured vari-
ance (A2). Another recent approach to LD mapping
entails modeling the underlying genetic haplotype struc-
ture and genealogies with complex functions of the
data’s joint likelihood (McPeek and Strahs 1999; Service
et al. 1999; Morris et al. 2000; Liu et al. 2001). Al-
though these methods show promise, they are compu-
tationally intensive and rely heavily on the ability to
estimate many population genetic parameters.
All of the above approaches can be viewed as hier-
archical models (Clayton 2000). For a second-stage dis-
tribution, the approaches of Lazzeroni (1998) and Cor-
dell and Elston (1999) focus on incorporating
correlations along the chromosome, while the joint like-
lihood approach attempts to estimate the correlations,
among haplotypes, due to population history. Our hi-
erarchical model incorporates both of these aspects: cor-
relations along the chromosome, by applying a spatial
structure based on the predicted decay of LD, and re-
lations among haplotypes, by including haplotype block
structure in the second-stage design matrix.
With multiple markers in a chromosomal region, one
can also undertake a haplotype-level analysis. This ap-
proach examines the association of combinations of al-
leles across several markers with the disease phenotype
(Schaid et al. 2002; Zaykin et al. 2002). However, dif-
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Figure 4 Linkage disequilibrium patterns for Crohn disease for a 103 SNPs in the 5q31 region. Unblackened circles () indicate the first-
stage estimates of the odds ratio obtained from a TDT analysis. Blackened circles (●) indicate the HLD estimates from a hierarchical analysis
with both spatial relations and haplotype blocks (model C with ). The solid lines are the second-stage regression coefficients, for˜tp 0.35 p
each haplotype block. For comparison to figure 3 from Rioux et al. (2001), the figure is truncated at an odds ratio of 3.0, thus removing SNP
79 at 617 kb with an odds ratio of 4.5.
ficulties arise in determining which markers are in the
haplotypes, how to estimate these haplotypes within
population-based samples (Fallin and Schork 2000),
and how to analyze the numerous haplotypes that result
when multiple markers are involved (Clayton and Jones
1999; Fallin et al. 2001). When individual markers are
grouped, there is the potential for increased power
(Bader 2001; Kaplan and Morris 2001; Morris and
Kaplan 2002), but these methods only give an estimate
of the joint effect for the grouped markers. Thus, re-
finement of the location of a disease polymorphism
along the chromosome within an associated group or
haplotype is not possible.
In contrast, incorporating the underlying haplotype
structure into a hierarchical model can result in esti-
mates for each marker that are weighted between con-
ventional pairwise measures of LD and haplotype-level
associations from haplotype blocks or marker groups.
In fact, one often analyzes fine-scale genetic data with
a two-step process, first calculating the pairwise mea-
sures of LD and then exploring the haplotype effects.
HLD offers a way to integrate both approaches—an
advantage when only genotype level data is available
and haplotypes must be estimated. The estimated hap-
lotypes can then be included in the analysis to refine
the pattern of pairwise LD, without relying solely upon
estimated effects obtained from the inexact haplotypes.
A key step in HLD is specification of t. Although
prespecifying t and using a two-stage estimation pro-
cedure may underestimate the posterior variance, we
are primarily interested in evaluating the pattern of LD
that is reflected in the posterior log odds ratio estimates.
Uncertainty in t can be incorporated with Markov
chain–Monte Carlo methods for parameter estimation
(Gilks et al. 1996). For example, an analysis of chro-
mosome 5q31 data (Daly et al. 2001) using model B
and WinBUGS (Spiegelhalter et al. 1999), estimates
. However, prespecification and sensitivitytp 0.55
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analysis using various values of t allow exploration of
the changing pattern of LD with varying influence of
the prior information. Such an analysis may give im-
portant insight into which markers and regions provide
the most reliable and stable estimates for the interpre-
tation of the pattern of LD.
Although our findings demonstrate the promise of
HLD, we are limited by building on conventional pair-
wise estimates and their ability to provide LD in the
presence of increased stochastic variability. This may
hinder our capacity to localize a disease locus when the
attributable fraction is small and the marker allele fre-
quencies vary considerably along a chromosomal re-
gion. Another potential limitation is that, although the
addition of prior information can dramatically improve
estimation, it can bias the final estimates. However, if
the information used is fairly accurate, the reduction in
the variance for the final estimates will far outweigh this
bias, yielding estimates that are more precise in terms
of reduced mean-squared errors (Greenland 2000a).
The methods presented here offer a flexible approach
to incorporate higher-level genetic information within
a wide variety of data structures. When information
exists on marker location and haplotype structure, it
can be used in a HLD approach to improve conven-
tional LD estimates. A generalized linear mixed model
(GLMM) allows for extension of the first stage to data
from family-based studies (Self et al. 1991; Schaid 1996;
Abecasis et al. 2000) and various disease outcomes
(George et al. 1999; Li and Fan 2000). Furthermore,
although this approach has been presented in the con-
text of fine-scale disease mapping by use of the log odds
ratio, stable estimates from HLD may facilitate exam-
ination of population dynamics when comparing LD
patterns obtained from any pairwise measure of LD.
HLD can be implemented in standard statistical soft-
ware packages (Witte et al. 1998, 2000) and scripts for
undertaking this analysis can be downloaded from our
Web site.
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Appendix
HLD Estimation
HLD estimates may be obtained by combining the
first- and second-stages in a semi-Bayes, empirical Bayes,
or fully Bayesian approach (Gelman et al. 1995; Green-
land 1997). For computational ease and conceptual sim-
plicity, we use a semi-Bayes approach with a two-stage
estimation procedure. A semi-Bayes approach may also
be viewed as a sensitivity analysis in which the influence
of second-stage information is varied in a hierarchical
model (Greenland and Poole 1994). In two-stage esti-
mation, a first-stage regression model is fitted by use of
conventional logistic regression to obtain the estimates
of , , and their SEs. Note that a separate first-stageˆb b
regression is undertaken for each marker, because high
colinearity among neighboring markers may lead to dif-
ficulties in fitting a first-stage model that includes all
markers (Neter et al. 1996). Additionally, because, in
fine-scale mapping, the association between each indi-
vidual marker and disease contributes to the overall pat-
tern of LD, one should not condition on additional
markers when obtaining the estimate of effect for each
marker.
The second-stage estimated prior means, , and cor-˜Zp
responding estimated covariance matrix, , can′ 1(ZWZ)
be obtained from a weighted least squares regression,
, where , and is′ 1 2 1ˆ ˆ ˆp˜p (ZWZ) ZWb Wp [V t T] V
a diagonal matrix with elements equal to the square of
the estimated SEs for (Morris 1983). Averaging theˆb
first- and second-stage estimates yields HLD estimates
˜ ˆ
˜ ( )bp BZp I B b . (A1)
The estimate of the HLD covariance matrix is given by
, where and′ ′ 1 ′˜ ˆCp V [I (IH) B] Hp Z (ZWZ) ZW
B is the estimated shrinkage matrix
1
2ˆ ˆ ˆ( )BpWVp V t T V . (A2)
From (A2), if the maximum-likelihood first-stage esti-
mates, , have large variance, , relative to the priorˆ ˆb V
variance, t2T, then B will also be large. This will result
in HLD estimates from (A1) weighted more heavily to-
ward the conditional second-stage mean, . Con-˜Zp
versely, if the first-stage estimates have small variances,
B will be small, resulting in final estimates, , close to˜b
the first-stage estimates, .ˆb
In semi-Bayes, t2T is prespecified. If it equals infinity,
we see from (A1) and (A2) that all second-stage infor-
mation is ignored, and the HLD estimate is equal to the
first-stage estimates, . At the other extreme, if t2 equalsˆb
zero, the HLD estimates will equal the second-stage con-
ditional means, . Intermediate values for t2 result in˜Zp
shrinkage estimation that is a compromise between the
first- and second-stage estimates and reflect the ranges
of residual odds ratios for the markers. For example,
after accounting for the relations defined in Z, a value
of implies a 95% prior certainty interval oftp 0.354
362 Am. J. Hum. Genet. 72:351–363, 2003
for the residual oddsexp (3.92# 0.354)p {0.5,2.0}
ratio (i.e., a fourfold range) (Greenland 2000b).
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